| CAS ID: | 936727-05-8 |
| Molecular Formula: | C24H18F2N2O5 |
| Molecular Weight: | 452.4 g/mol |
| Monoisotopic Mass: | 452.1184 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | VX-809 | VRT-826809 | LUMACAFTOR |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17/h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31) | See All |
| InChI Key: | UFSKUSARDNFIRC-UHFFFAOYSA-N | |
| Smiles: | Cc1ccc(NC(=O)C2(CC2)c3ccc4OC(F)(F)Oc4c3)nc1c5cccc(c5)C(=O)O | See All |
| Molfile: | Download |
Reference Record 1
| PubMed ID | 25825526 | Target ID | |
| Uniprot ID | Name | ||
| Model | vitro,mice | Fibrosis Disease | Cystic fibrosis |
| Process I | |||
| Process II | |||
| Process III | |||
| Mechanism | |||
Trial Record 1
| ClinicalTrial ID | NCT00865904 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | March 19, 2009 | Last Verified | August 28, 2015 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 2
| ClinicalTrial ID | NCT02797132 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | June 13, 2016 | Last Verified | October 30, 2018 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 3
| ClinicalTrial ID | NCT03125395 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Active, not recruiting |
| First Received | April 24, 2017 | Last Verified | January 18, 2019 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 4
| ClinicalTrial ID | NCT01897233 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | July 11, 2013 | Last Verified | June 20, 2017 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 5
| ClinicalTrial ID | NCT02875366 | Disease | Cystic fibrosis |
| Phase | Phase 4 | Status | Completed |
| First Received | August 23, 2016 | Last Verified | December 2, 2017 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 6
| ClinicalTrial ID | NCT01225211 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | October 20, 2010 | Last Verified | October 5, 2015 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 7
| ClinicalTrial ID | NCT01807949 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | March 8, 2013 | Last Verified | September 27, 2016 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 8
| ClinicalTrial ID | NCT01807923 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | March 8, 2013 | Last Verified | August 31, 2015 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 9
| ClinicalTrial ID | NCT01931839 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 29, 2013 | Last Verified | May 12, 2017 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 10
| ClinicalTrial ID | NCT02653027 | Disease | Cystic fibrosis |
| Phase | Not Applicable | Status | Withdrawn |
| First Received | January 12, 2016 | Last Verified | May 21, 2018 |
| Sponsor | Massachusetts General Hospital | ||
Trial Record 11
| ClinicalTrial ID | NCT02807415 | Disease | Cystic fibrosis |
| Phase | Status | Recruiting | |
| First Received | June 21, 2016 | Last Verified | February 25, 2019 |
| Sponsor | Hannover Medical School | ||
Trial Record 12
| ClinicalTrial ID | NCT03061331 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | February 23, 2017 | Last Verified | October 2, 2018 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 13
| ClinicalTrial ID | NCT02544451 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Active, not recruiting |
| First Received | September 9, 2015 | Last Verified | October 2, 2018 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 14
| ClinicalTrial ID | NCT02514473 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 3, 2015 | Last Verified | October 23, 2017 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 15
| ClinicalTrial ID | NCT01899105 | Disease | Cystic fibrosis |
| Phase | Phase 1 | Status | Completed |
| First Received | July 15, 2013 | Last Verified | April 3, 2014 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 16
| ClinicalTrial ID | NCT02858843 | Disease | Cystic fibrosis |
| Phase | Not Applicable | Status | Terminated |
| First Received | August 8, 2016 | Last Verified | May 21, 2018 |
| Sponsor | Massachusetts General Hospital | ||
Trial Record 17
| ClinicalTrial ID | NCT02390219 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | March 17, 2015 | Last Verified | December 6, 2017 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 18
| ClinicalTrial ID | NCT02823470 | Disease | Cystic fibrosis |
| Phase | Phase 4 | Status | Terminated |
| First Received | July 6, 2016 | Last Verified | September 27, 2018 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 19
| ClinicalTrial ID | NCT01910415 | Disease | Cystic fibrosis |
| Phase | Phase 1 | Status | Completed |
| First Received | July 29, 2013 | Last Verified | August 11, 2014 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 20
| ClinicalTrial ID | NCT01768663 | Disease | Cystic fibrosis |
| Phase | Phase 1 | Status | Completed |
| First Received | January 15, 2013 | Last Verified | November 15, 2013 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 21
| ClinicalTrial ID | NCT01216046 | Disease | Cystic fibrosis |
| Phase | Phase 1 | Status | Completed |
| First Received | October 7, 2010 | Last Verified | January 18, 2012 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 22
| ClinicalTrial ID | NCT00966602 | Disease | Cystic fibrosis |
| Phase | Phase 1 | Status | Completed |
| First Received | August 27, 2009 | Last Verified | January 5, 2010 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
| PubChem: | 16678941 |
| ChEMBL: | CHEMBL2103870 |